ClinicalTrials.gg
Not yet recruitingNCT07008833REDEMPTEDUpdated Oct 29, 2026

Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer

An interventional study of Radiochemotherapy and Radical cystectomy in Muscle Invasive Bladder Cancer, sponsored by Brazilian Clinical Research Institute. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Brazilian Clinical Research Institute · Not applicable, Interventional, and Treatment

How we know

Updated Oct 29, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
336
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 33 studies in Urinary Bladder Neoplasms with a site in Brazil — 10 open to participants now, 17 under way, 11 of them phase 3. Urinary Bladder Neoplasms · Brazil.

Planned enrollment
19th of 31
336 · median 390
Started
2026
with 4 others
No phase
3 of 33
2 open now
Primary completion
2031-12
later than 16 of 16 live
Registered
27th of 33
by date
Lead sponsor
1 of 33
Brazilian Clinical Research Institute

Among the 33 studies in Urinary Bladder Neoplasms with a site in Brazil, this one is the 19th largest by planned enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2026, is one of 3 with no phase, reaches primary completion later than 16 of the 16 other live ones, and was the 27th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

10 of the 33 studies in Urinary Bladder Neoplasms with a site in Brazil are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Urinary Bladder Neoplasms with a site in Brazil, or all of them as a file.
02

Study summary

Your text is mostly clear and well-structured. Here's a slightly polished version for improved clarity and flow:

This is a randomized, non-inferiority study comparing radiochemotherapy to radical cystectomy in patients with muscle-invasive bladder cancer. The primary outcome is the evaluation of the non-inferiority of metastasis-free survival between the two treatments.

The study population includes individuals of both sexes, aged 18 years and older, diagnosed with pure or predominant urothelial carcinoma. Participants will be randomized in a 1:1 ratio, with Arm 1 receiving maximal TURBT followed by neoadjuvant chemotherapy and radiotherapy, and Arm 2 receiving TURBT followed by neoadjuvant chemotherapy with cisplatin, followed by radical cystectomy and bilateral pelvic lymphadenectomy.

03

Conditions studied

  • Muscle Invasive Bladder Cancer

Keywords

  • Bladder cancer
  • Radiochemotherapy
  • Radical cystectomy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥ 18 years of age.
  2. Pure or predominant urothelial carcinoma (including other histologic subtypes, with the exception of small cell carcinoma, as a minority component).
  3. Performance status of 0 to 1, according to the (ECOG) criteria.
  4. of ≥ 3 months.
  5. confirmed T2, T3, or T4a stage bladder cancer (pure or predominant urothelial carcinoma) cN0 or cN1 or cN2 (if lymph nodes within the surgical and radiation fields and size ≤ 2 cm).
  6. Patients who are candidates for cisplatin and have undergone TURBT (preferably maximal) prior to treatment.
  7. Adequate bladder function (defined as the ability to store and void urine effectively, without symptoms of dysfunction or incontinence).
  8. ≥ 1500/mm³.
  9. count ≥ 100,000/mm³.
  10. count > 10 g/dL.
  11. greater than 40 mL/min.
  12. Serum \< 1.5 times the reference range and and SGPT \< 1.5 times the upper limit of the normal reference range.
  13. Absence of comorbidities that contraindicate treatment.
  14. Capable of giving signed and dated prior to any mandatory study-specific procedures, sampling, and analyses, which includes compliance with the requirements and restrictions listed in the informed consent form and study protocol.
  15. For inclusion in i) optional exploratory genetic research and ii) optional biomarker research, patients must meet the following criteria:

    • Provide informed consent for genetic research prior to sample collection.
    • Provide informed consent for biomarker research prior to sample collection.
    • If a patient declines to participate in optional biomarker research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study.

Exclusion criteria

Exclusion Criteria:

  1. Presence of multiple primary tumors or multiple foci of carcinoma in situ (CIS) (including in the upper tract) that are not candidates for bladder preservation with radiochemotherapy (definition at the discretion of the investigator).
  2. Age > 80 years.
  3. Pure adenocarcinoma or pure squamous carcinoma or pure small cell or large cell neuroendocrine carcinoma, micropapillary, sarcomatoid or nested.
  4. or unresectable disease.
  5. Sensory neuropathy Grade ≥ 2.
  6. Hearing impairment Grade ≥ 2.
  7. Having a known additional that has progressed or required active treatment in the last 5 years, except superficial bladder cancer and/or carcinoma in situ, basal cell carcinoma of the skin or carcinoma in situ of the cervix.
  8. cardiovascular disease - functional class III-IV according to the (NYHA) Classification of heart failure.
  9. Patients considered to be at high medical risk due to severe and uncontrolled disease, active or non-malignant systemic disease, and severe or potentially severe infection that may affect response to treatment or increase the risk of adverse events.
  10. patients.
  11. Inflammatory bowel disease.
  12. Patients with known active hepatitis (i.e., or C).
  13. Patients receiving any prior systemic chemotherapy in the last 5 years for other tumors and at any time for muscle-invasive bladder cancer.
  14. Patients who have received prior systemic immunotherapy at any time, either in the setting of non-muscle-invasive bladder cancer or in treatment for other types of cancer.
  15. Prior pelvic radiotherapy.
  16. Patients, male or female, who do not agree to use an effective method of throughout treatment and until 6 months after discontinuation of treatment.
  17. Women who are pregnant or currently breastfeeding. 18. The investigator's judgment that the patient should not participate in the study if the patient is unlikely to comply with the procedures, restrictions, and requirements.

19. Prior Randomization to the present study.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
336 participants (estimated)

Study arms

  • Other
    Arm 1

    Maximum TURBT + neoadjuvant chemotherapy with cisplatin + radiotherapy

    Procedure: Radiochemotherapy

  • Other
    Arm 2

    TURBT + neoadjuvant chemotherapy with cisplatin + radical cystectomy, bilateral pelvic lymphadenectomy + reconstruction

    Procedure: Radical cystectomy

Interventions

  • ProcedureRadiochemotherapy

    Maximum TURBT will be followed by neoadjuvant chemotherapy with cisplatin at a dose of 35 mg/m². After 2-6 weeks of neoadjuvant chemotherapy, patients will receive radiotherapy for 4 weeks, with concomitant cisplatin at a dose of 40 mg/m² weekly.

  • ProcedureRadical cystectomy

    TURBT will be followed by neoadjuvant chemotherapy with cisplatin at a dose of 35 mg/m², followed by radical cystectomy, bilateral pelvic lymphadenectomy, and reconstruction with either a Bricker procedure or a neobladder.

06

What researchers measure

Primary outcomes

  1. Metastasis-free survival

    The primary outcome is the assessment of the non-inferiority of metastasis-free survival between radiochemotherapy and radical cystectomy.

    Time frame: The time from the start of treatment until detection of 230 metastases in other organs or tissues outside the bladder (including pelvic lymph nodes).or until death from any cause of the patient, estimated to be up to 8 years

Secondary outcomes

  1. Overall survival

    Overall survival of radiochemotherapy versus radical cystectomy.

    Time frame: The duration from treatment initiation until the study accrues 230 patients with a primary event, or 6 years of follow-up

  2. Muscle-invasive bladder cancer-free survival

    Time frame: The duration from treatment initiation until the study accrues 230 patients with a primary event, or 6 years of follow-up

  3. Incidence of tumors in the upper tract (in both arms)

    The proportion of patients who develop new tumors in the upper urinary tract in 6 years

    Time frame: The duration from treatment initiation until the study accrues 230 patients with a primary event, or 6 years of follow-up

  4. Adverse Events assessment

    All adverse events will be collected and classified according to CTCAE v5.0. The protocol defines the following adverse events of special interest for the Radical Cystectomy group: surgical (infections, bleeding, organ injury, thromboembolism), postoperative (fistula, stricture, hernia, delayed healing), and long-term complications (renal insufficiency, GI disorders, sexual dysfunction, body image issues). And Chemoradiotherapy group: acute effects (cystitis, proctitis, enteritis, nausea, vomiting) and severe toxicities (hematologic toxicity, grade 3-4 diarrhea, skin toxicity).

    Time frame: The duration from treatment initiation until the study accrues 230 patients with a primary event, or 6 years of follow-up

  5. Quality of Life assessment

    Assessment of the perception of patients with bladder cancer about their general well-being, including symptoms of the disease, impact of treatment, psychological and emotional aspects, and the ability to perform physical and social activities, measured through the EORTC QLQ-BLM30 questionnaire.

    Time frame: The duration from treatment initiation until the study accrues 230 patients with a primary event, or 6 years of follow-up

07

Study locations

1 site
  • Brazilian Clinical Research Institute
    São Paulo, São Paulo 01404100, Brazil
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2031, 60 months later.

Of 237 non-industry interventional studies with no phase under Urinary Bladder Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 69. This study's planned 60 months is above that.

Counting every sponsor, half of 246 studies reached it within 38 months; a quarter within 18 and three quarters within 69.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Dec 2026, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
Jun 6, 2025
StartEst.
Dec 2026was Jun 2026
Primary completionEst.
Dec 2031
CompletionEst.
Feb 2032
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→Dec 2026
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Start date Jun 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07008833
Lead sponsor
Brazilian Clinical Research Institute
Collaborators
Ministry of Science and Technology, Brazil
Responsible party
Sponsor
First posted
Jun 6, 2025
Start date
Dec 2026 (estimated)
Primary completion
Dec 2031 (estimated)
Completion
Feb 2032 (estimated)
Last update
Oct 29, 2026

Study contacts

Fernando C Maluf, MD
Contact
maluffc@uol.com.br
55 11 59047339

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion